Biotech hopes for drug test windfall over Rett syndrome
MELBOURNE: Listed biotech Neuren is on track for a $US105m ($152m) windfall from US pharmaceutical
MELBOURNE: Listed biotech Neuren is on track for a $US105m ($152m) windfall from US pharmaceutical
FEATURED
NDIS cartoon on government policy published today
NRL coach now diagnosed with form of neurodegenerative disorder
Wheelchair taxi users face service cuts as diesel costs soar
Extraordinary gene cream now set to heal lifelong wound
Bank provides inaugural $480m social loan to disability provider
One Nation could pick up seats from NDIS reform